CONNECT WITH US
Tech

Tech

PharmEasy Parent API Holdings’ FY26 Loss Declines 67% YoY To ₹520 Cr

Inc42 - All News logo

Published on

Add as a preferred source on Google
PharmEasy Parent API Holdings’ FY26 Loss Declines 67% YoY To ₹520 Cr

PharmEasy parent API Holdings narrowed its consolidated net loss by 67% to ₹520 Cr in the fiscal year ended March 2026 (FY26) from ₹1,572 Cr in the previous fiscal, with its operating revenue growing 12.7% YoY to ₹6,618.5 Cr.

The company attributed the improvement to its focus on customer experience, higher-value profitable segments, capacity utilisation, increasing wallet share and leveraging digital capabilities.

In its FY26 annual report, API Holdings said it improved margins by focusing on higher-margin products, particularly its private label brands, and optimising discounts in its B2R business.

Including other income of ₹70.8 Cr, the company’s total revenue stood at ₹6,689.2 Cr for FY26. However, it continued to report a loss before tax of ₹456.1 Cr.

In the first quarter of FY27, API Holdings reported a 10% YoY increase in revenue to ₹1,754 Cr  while EBITDA rose to ₹39.3 Cr. Gross margin improved to 21.4% from 19.9% in FY26, and EBITDA margin reached 2.2%. Its B2B business grew 8.2% YoY to ₹1,006 Cr revenue and turned EBITDA-positive at ₹70 lakh. 

The company said that PharmEasy’s B2C business posted ₹348 Cr revenue, with EBITDA losses narrowing to ₹17 Cr. Thyrocare reported 24% YoY revenue growth to ₹240 Cr, processed 5.4 Mn patients and conducted 55.2 Mn tests.

API Holdings’ consolidated expenses declined marginally by 0.9% to ₹7,146.7 Cr in FY26 from ₹7,208.6 Cr in the previous fiscal year. Purchases of stock-in-trade remained its largest expense, while lower employee benefit costs contributed to the overall reduction.


Source link
Related Topics:Tech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.